| Evofem Biosciences is a biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. Co. is utilizing its proprietary Multipurpose Vaginal pH Regulator (MVP-R) platform to product candidates for several potential indications, including prevention of pregnancy and prevention of certain sexually transmitted infections. Co. is developing its primary MVP-R product candidate, Phexxi, a non-hormonal, woman-controlled vaginal gel, for three potential indications: prevention of pregnancy, prevention of urogenital Chlamydia trachomatis infection and prevention of urogenital Neisseria gonorrhoeae infection. The EVFM YTD return is shown above.
The YTD Return on the EVFM YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether EVFM YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the EVFM YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.